Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

3/6/2018 Rating of Russian Pharmaceutical Distributors (2017)

The begging of 2018 was quite eventful for the Russian pharmaceutical wholesale. First, the bankruptcy process of Rosta started in January, with a rather high level of debt overburden for the pharmaceutical retail, which is estimated to be 10-11% of the annual volume of the retail market by Protek. So, the external prosperity of wholesale companies (by the end of 2017, only 4 out of the 15 largest companies has had their market share reduced) can be replaced by a recession at any moment.

3/1/2018 Database Update: Pharmaceutical Drug Production in Russia (January 2018)

The new year for the Russian pharmaceutical industry did not start that well. In January, Russia dispatched 22 bln RUB worth of pharmaceuticals (dispatch prices, VAT included) to the market, which is in monetary terms 3.4% lower than that of January 2017. The growth rates in physical terms are even worse, with a 7.2% decline and 0.29 bln units. The decline was largely due to over-the-counter drugs, with a 13% decline over the year. The dispatch of the Rx category has risen by 4%, though.

2/22/2018 2017 Rating of Russian Pharmacy Chains

At the beginning of the year, pharmaceutical drug sale in non-pharmaceutical stores was once again one of the central topics for the Russian pharmaceutical industry. The industry professionals made an unambiguous assessment of the initiative, which could have called it quits. However, the regulators had other ideas. In December 2017, a draft federal law was submitted for public discussion.

2/20/2018 Database Update: Veterinary Drug and API Import to Russia (December 2017)

Among veterinary products, feed supplements led the way in import volume in 2017, with 32.8 mln RUB (free circulation prices). Since 2016, feed supplement import has increased by 6.2% in monetary terms. Veterinary drug import has risen by 7.6% in monetary terms, with the volume amounting to more than 23.8 mln RUB. Veterinary API import shows the best progress with 12.9% and 1.8 bln RUB.

2/16/2018 Database Update: API Import to Russia (December 2017)

Between January and December 2017, Russia imported 74 bln RUB worth of APIs (free circulation prices plus VAT). Pharmacopoeial APIs take up most of it (97.5%) and contributed to the total import volume in monetary terms, which has risen by 22% in comparison with the same period in 2016. Pharmacopoeial API import has risen by 23% over the year, and imports of technical raw materials have decreased by 5.5%.

All news [77]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.